There were 2,384 press releases posted in the last 24 hours and 440,432 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image